What is the definition of Light Chain Deposition Disease?

Light chain deposition disease (LCDD) is a rare condition characterized by the deposition of specific proteins (monoclonal light chains) in the kidneys and other organs. Light chains are used to make antibodies that the body needs to fight infection. People with LCDD make too many light chains, which get deposited in many body tissues. While LCDD can occur in any organ, the kidneys are always involved. Signs and symptoms of LCDD may include protein in the urine; decreased kidney function; and/or nephrotic syndrome. Rarely, a person with LCDD may have symptoms from cardiac (heart) or liver involvement.

The underlying cause of LCDD is unknown. It is often associated with multiple myeloma. LCDD may progress to multiple myeloma, or it may be present with multiple myeloma when it is first diagnosed.

The goal of treating LCDD is to slow the production of light chains and their damage to organs. Treatment may include chemotherapy with a drug called Bortezomib; autologous stem cell transplantation; immunomodulatory drugs; and/or kidney transplant. If untreated, end-stage renal disease occurs in 70% of cases.

What are the alternative names for Light Chain Deposition Disease?

  • Light-chain deposition disease
  • Condition: Cardiac Amyloidosis and Cardiac Light Chain Deposition Disease
  • Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  • Treatment Used: Autologous Stem Cell Transplant
  • Number of Patients: 50
  • Published —
This study tested the safety and efficacy of using an autologous stem cell transplant to treat patients with cardiac amyloidosis and cardiac light chain deposition disease.
Clinical Trial
  • Status: Active, not recruiting
  • Phase: Phase 1
  • Intervention Type: Drug, Other
  • Participants: 36
  • Start Date: March 2013
Phase I Study of Pomalidomide, Bortezomib, and Dexamethasone (PVD) as First-Line Treatment of AL Amyloidosis or Light Chain Deposition Disease
Clinical Trial
  • Status: Active, not recruiting
  • Phase: Phase 2
  • Intervention Type: Drug, Procedure, Genetic, Other
  • Participants: 35
  • Start Date: September 2007
A Multicenter Phase II Trial of Bortezomib (Velcade), Melphalan, and Dexamethasone (V-MD) in Patients With Symptomatic AL-Amyloidosis or Light Chain Deposition Disease